Bluebird Bio’s Killer T-Cells Have “Impressive” Results Against Myeloma – Forbes
Forbes |
Bluebird Bio’s Killer T–Cells Have “Impressive” Results Against Myeloma
Forbes based Bluebird Bio and Summit, N.J.-based Celgene, is a form of CAR-T, short for chimeric antigen receptor T–cell, for the type of white blood cell and the modifications made to it. This CAR-T targets a protein found in multiple myeloma cells called B … Cellular Therapies for Multiple Myeloma: A Paradigm ShiftCancer Network Bluebird Bio CAR–T delays multiple myeloma progression by one year, but is that enough?STAT #ASCO18: Bluebird & Celgene’s CAR–T nears 1 year of PFS in multiple myelomaFierceBiotech Business Wire (press release) –Reuters all 7 news articles » |
Infosurhoy |
Limiting toxicity of CAR T therapy in acute myeloid leukemia
Science Daily “This therapy is meant to be a true living drug, and we know that CAR T cells can live on in patients’ bodies for years after infusion, so turning them off would be self-defeating,” said the study’s co-senior author Saar I. Gill, MD, PhD, an assistant … Penn-developed Approach Could Limit Toxicity of CAR T Cell Therapy in Acute Myeloid LeukemiaNewswise (press release) A Cancer Patient Is In Remission Thanks To One Genetically …IFLScience A Cancer Patient Is In Remission Thanks To One Genetically Engineered Immune CellBrinkwire (press release) |